SI3448430T1 - Uporaba inhibitorja acetilholinesteraze in idalopirdina za zmanjšanje padcev pri bolnikih s parkinsonovo boleznijo - Google Patents

Uporaba inhibitorja acetilholinesteraze in idalopirdina za zmanjšanje padcev pri bolnikih s parkinsonovo boleznijo

Info

Publication number
SI3448430T1
SI3448430T1 SI201731371T SI201731371T SI3448430T1 SI 3448430 T1 SI3448430 T1 SI 3448430T1 SI 201731371 T SI201731371 T SI 201731371T SI 201731371 T SI201731371 T SI 201731371T SI 3448430 T1 SI3448430 T1 SI 3448430T1
Authority
SI
Slovenia
Prior art keywords
idalopirdine
parkinson
disease patients
acetylcholinesterase inhibitor
reducing falls
Prior art date
Application number
SI201731371T
Other languages
English (en)
Inventor
Jong Inge E M De
Aaron Kucinski
Martin Sarter
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of SI3448430T1 publication Critical patent/SI3448430T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201731371T 2016-04-26 2017-04-25 Uporaba inhibitorja acetilholinesteraze in idalopirdina za zmanjšanje padcev pri bolnikih s parkinsonovo boleznijo SI3448430T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201600248 2016-04-26
PCT/EP2017/059739 WO2017186686A1 (en) 2016-04-26 2017-04-25 Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients
EP17719255.6A EP3448430B1 (en) 2016-04-26 2017-04-25 Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients

Publications (1)

Publication Number Publication Date
SI3448430T1 true SI3448430T1 (sl) 2023-08-31

Family

ID=58632402

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201731371T SI3448430T1 (sl) 2016-04-26 2017-04-25 Uporaba inhibitorja acetilholinesteraze in idalopirdina za zmanjšanje padcev pri bolnikih s parkinsonovo boleznijo

Country Status (27)

Country Link
US (1) US10383849B2 (sl)
EP (1) EP3448430B1 (sl)
JP (1) JP6992004B2 (sl)
KR (1) KR102473545B1 (sl)
CN (1) CN109069650A (sl)
AU (1) AU2017256623B2 (sl)
BR (1) BR112017026928B1 (sl)
CA (1) CA3020557C (sl)
CL (1) CL2018003013A1 (sl)
CY (1) CY1126138T1 (sl)
DK (1) DK3448430T3 (sl)
ES (1) ES2949288T3 (sl)
FI (1) FI3448430T3 (sl)
HR (1) HRP20230693T8 (sl)
HU (1) HUE062626T2 (sl)
IL (1) IL262546B (sl)
LT (1) LT3448430T (sl)
MX (1) MX2018013031A (sl)
PL (1) PL3448430T3 (sl)
PT (1) PT3448430T (sl)
RS (1) RS64307B1 (sl)
RU (1) RU2742173C2 (sl)
SG (1) SG11201809297UA (sl)
SI (1) SI3448430T1 (sl)
TW (1) TW201806621A (sl)
WO (1) WO2017186686A1 (sl)
ZA (1) ZA201806864B (sl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201909895UA (en) * 2017-05-24 2019-11-28 H Lundbeck As Combination of a 5-ht6 receptor antagonist and an acetylcholinesterase inhibitor for use in the treatment of alzheimer's disease in a patient subpopulation carrying apoe4 alleles
EP3727043A4 (en) * 2017-12-22 2021-07-07 Neurocea, LLC COMPOSITIONS AND METHODS OF TREATMENT IN CONNECTION WITH THE CASE AND FREQUENCY OF NEURODEGENERATIVE DISEASES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818914D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
EP1379239B1 (en) * 2001-03-29 2007-09-12 Eli Lilly And Company N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor
ATE511843T1 (de) * 2005-04-04 2011-06-15 Eisai R&D Man Co Ltd Dihydropyridin-verbindungen für neurodegenerative erkrankungen und demenz
PE20071143A1 (es) * 2006-01-13 2008-01-20 Wyeth Corp Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6
CN101500611A (zh) * 2006-06-23 2009-08-05 埃斯蒂维实验室股份有限公司 胆碱脂酶抑制剂与具有5-ht6受体亲和力的化合物的组合
EP2508177A1 (en) * 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
RU2393158C1 (ru) * 2008-10-06 2010-06-27 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 3-АРИЛСУЛЬФОНИЛ-ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
JO3459B1 (ar) * 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر

Also Published As

Publication number Publication date
US20170304267A1 (en) 2017-10-26
CA3020557C (en) 2024-05-21
AU2017256623A1 (en) 2018-11-01
JP2019519480A (ja) 2019-07-11
SG11201809297UA (en) 2018-11-29
JP6992004B2 (ja) 2022-02-03
AU2017256623B2 (en) 2022-07-21
RU2018135846A3 (sl) 2020-09-30
PT3448430T (pt) 2023-07-11
RU2742173C2 (ru) 2021-02-02
HRP20230693T8 (hr) 2023-11-10
PL3448430T3 (pl) 2023-08-21
HUE062626T2 (hu) 2023-11-28
ZA201806864B (en) 2020-01-29
CL2018003013A1 (es) 2018-12-14
BR112017026928B1 (pt) 2023-04-11
EP3448430A1 (en) 2019-03-06
RU2018135846A (ru) 2020-05-26
DK3448430T3 (da) 2023-07-03
CN109069650A (zh) 2018-12-21
MX2018013031A (es) 2019-01-17
LT3448430T (lt) 2023-07-25
EP3448430B1 (en) 2023-06-07
IL262546B (en) 2022-05-01
KR20180133869A (ko) 2018-12-17
BR112017026928A2 (pt) 2018-08-14
CA3020557A1 (en) 2017-11-02
US10383849B2 (en) 2019-08-20
WO2017186686A1 (en) 2017-11-02
FI3448430T3 (fi) 2023-06-20
HRP20230693T1 (hr) 2023-10-13
IL262546A (en) 2018-12-31
TW201806621A (zh) 2018-03-01
KR102473545B1 (ko) 2022-12-01
CY1126138T1 (el) 2023-11-15
ES2949288T3 (es) 2023-09-27
RS64307B1 (sr) 2023-07-31

Similar Documents

Publication Publication Date Title
IL246579B (en) Compounds that inhibit the activity of 2lrrk and their use in the treatment of Parkinson's disease
IL252943A0 (en) Sunitinib formulations and methods of using them for the treatment of eye diseases
IL281445A (en) Therapeutic nanoparticles and methods for their use
IL259862B (en) Inhibitors of proton tyrosine kinase and methods of using them
IL274578A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
PT3302454T (pt) Composições para utilização no tratamento da doença de parkinson e distúrbios associados
IL264407A (en) Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases
HK1257583A1 (zh) 預防和治療脂肪代謝紊亂及其相關病症的藥物及其用途
EP2949651A4 (en) SUBSTITUTED BENZOTHIAZOLES AND THEIR THERAPEUTIC APPLICATIONS FOR THE TREATMENT OF HUMAN DISEASES
GB201519557D0 (en) Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions
ZA201903828B (en) Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases
IL262546B (en) Use of an acetylcholinesterase inhibitor and idalopyridine to reduce falls in Parkinson's patients
RS63321B1 (sr) Formulacije za primenu u lečenju endometrioze i poremećaja koji su sa njom u vezi
EP3518951C0 (en) COMPOSITIONS FOR USE IN THE TREATMENT OF OSTEOPOROSIS AND Fractures
IL272495A (en) Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases
HK1223014A1 (zh) 用於在預防和/或治療多動性運動障礙中使用的治療劑
EP3261446A4 (en) Methods and compositions for the treatment or prevention of parkinson's disease
PL3137097T3 (pl) Leczenie i profilaktyka choroby Alzheimera (AD)
PL3137093T3 (pl) Leczenie i profilaktyka choroby Alzheimera (AD)
PT3137094T (pt) Tratamento e prevenção da doença de alzheimer (da)
IL265911A (en) Epilimod preparations and methods of using them in the treatment of Alzheimer's disease
ZA201801945B (en) Compositions and methods for the treatment of parkinson's disease
SG11201701618SA (en) Use of tetrahydropyridines in the treatment of sodium channel related disease and disorders
GB201718838D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
GB201712742D0 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases